MARKET

NVCR

NVCR

Novocure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

125.58
-1.73
-1.36%
Opening 14:27 09/27 EDT
OPEN
126.27
PREV CLOSE
127.30
HIGH
126.66
LOW
123.29
VOLUME
157.67K
TURNOVER
--
52 WEEK HIGH
232.76
52 WEEK LOW
106.36
MARKET CAP
13.02B
P/E (TTM)
-2414.9038
1D
5D
1M
3M
1Y
5Y
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
Benzinga · 09/14 12:34
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 09/14 11:50
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
ST. HELIER, Jersey, September 14, 2021--Novocure has entered into a clinical trial collaboration with Roche to evaluate TTFields as part of a novel combination to treat pancreatic cancer.
Business Wire · 09/14 11:00
NovoCure, Roche Team Up to Develop Tumor Treating Fields for Potential Treatment of Pancreatic Cancer
MT Newswires · 09/14 09:08
FDA Grants Breakthrough Device Designation to the NovoTTF-200T(TM) System for Advanced Liver Cancer
Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T System, a Tumor Treating Fields (TTFields) delivery system intended for use together with atezolizumab and...
Business Wire · 09/09 12:14
NovoCure Gets FDA Breakthrough Device Designation for Tumor Treating Fields in Liver Cancer
MT Newswires · 09/09 10:24
Insider Sell: Novocure
MT Newswires · 09/07 16:57
Wedbush Adjusts NovoCure PT to $101 From $148, Maintains Underperform Rating
MT Newswires · 09/02 12:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVCR. Analyze the recent business situations of Novocure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVCR stock price target is 177.14 with a high estimate of 250.00 and a low estimate of 101.00.
EPS
Institutional Holdings
Institutions: 476
Institutional Holdings: 79.72M
% Owned: 76.92%
Shares Outstanding: 103.65M
TypeInstitutionsShares
Increased
121
6.61M
New
76
641.13K
Decreased
111
4.20M
Sold Out
42
583.39K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.66%
Healthcare Equipment & Supplies
-2.00%
Key Executives
Chairman/Executive Director
William Doyle
President/Chief Executive Officer/Director
Asaf Danziger
Chief Financial Officer
Ashley Cordova
Corporate Executive
Ely Benaim
Chief Operating Officer
Wilhelmus Groenhuysen
Chief Human Resource Officer
William Burke
Vice President
Michael Ambrogi
General Counsel
Todd Longsworth
Other
Frank Leonard
Other
Pritesh Shah
Lead Director/Independent Director
William Vernon
Independent Director
Jeryl Hilleman
Independent Director
David Hung
Independent Director
Kinyip Gabriel Leung
Independent Director
Martin Madden
Independent Director
Sherilyn McCoy
Independent Director
Timothy Scannell
No Data
About NVCR
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Webull offers kinds of Novocure Ltd stock information, including NASDAQ:NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.